公开(公告)号：US20210322323A1

公开(公告)日：2021-10-21

申请号：US17228753

申请日：2021-04-13

Applicant: Janssen Biotech, Inc.

Inventor： Jacqueline Maximilien ,  Gopal Rajan

IPC: A61K9/28 ,  A61K9/20 ,  A61K31/5377 ,  A61K9/00

Abstract: Provided herein are pharmaceutical compositions for oral administration comprising N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide or a pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient; and a combination of (i) a cellulose derivative and (ii) a sugar or polyol as diluents. The disclosed compositions are characterized by improved manufacturability, while maintaining the pharmaceutical benefits of minimizing the effect according to changes in pH environment in the stomach, possessing excellent stability, and exhibiting good bioavailability.

公开(公告)号：US12138351B2

公开(公告)日：2024-11-12

申请号：US17228753

申请日：2021-04-13

Applicant: Janssen Biotech, Inc.

Inventor： Jacqueline Maximilien ,  Gopal Rajan

IPC: A61K9/28 ,  A61K9/00 ,  A61K9/20 ,  A61K31/5377

Abstract: Provided herein are pharmaceutical compositions for oral administration comprising N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide or a pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient; and a combination of (i) a cellulose derivative and (ii) a sugar or polyol as diluents. The disclosed compositions are characterized by improved manufacturability, while maintaining the pharmaceutical benefits of minimizing the effect according to changes in pH environment in the stomach, possessing excellent stability, and exhibiting good bioavailability.